Monoclonal antibody-based immunotherapy for multiple myeloma

Immunotherapy

Volumn 4, Issue 9, 2012, Pages 919-938

  Danylesko, Ivetta ^a   Beider, Katia ^a   Shimoni, Avichai ^a   Nagler, Arnon ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

humoral immunity; immunotherapy; molecular targets; monoclonal antibodies; multiple myeloma

Indexed keywords

BEVACIZUMAB; BHQ 880; BORTEZOMIB; BT 062; CANCER ANTIBODY; CD20 ANTIBODY; CD40 LIGAND MONOCLONAL ANTIBODY; CD74 ANTIGEN; DACETUZUMAB; DARATUMUMAB; DENOSUMAB; DEXAMETHASONE; ELOTUZUMAB; HULUC 63; IPH 2101; LENALIDOMIDE; LORVOTUZUMAB MERTANSINE; LUCATUMUMAB; MELPHALAN; MONOCLONAL ANTIBODY; NATALIZUMAB; P SELECTIN GLYCOPROTEIN LIGAND 1; PIDILIZUMAB; PLACEBO; PREDNISONE; RITUXIMAB; SILTUXIMAB; SYNDECAN 1; TOCILIZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CELL THERAPY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNOTHERAPY; LYMPHOCYTE; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; MULTIPLE MYELOMA; TUMOR MICROENVIRONMENT;

EID: 84867380709     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.12.82     Document Type: Review

References (166)

1. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiple myeloma. Lancet 374(9686), 324-339 (2009).
2. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Emerging therapies for multiple myeloma. Expert Opin Emerg. Drugs 14(1), 99-127 (2009).
3. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N. Engl. J. Med. 348(19), 1875-1883 (2003). (Pubitemid 36532313)
4. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10(5), 317-327 (2010).
5. Kastritis E, Charidimou A, Varkaris A, Dimopoulos MA. Targeted therapies in multiple myeloma. Target. Oncol. 4(1), 23-36 (2009).
6. Di Bernardo A, Macor P, Guarnotta C et al. Humoral immunotherapy of multiple myeloma: perspectives and perplexities. Expert Opin Biol. Ther. 10(6), 863-873 (2010).
7. Kapoor P, Greipp PT, Morice WG, Rajkumar SV, Witzig TE, Greipp PR. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br. J. Haematol. 141(2), 135-148 (2008). (Pubitemid 351406208)
8. Robillard N, Avet-Loiseau H, Garand R et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 102(3), 1070-1071 (2003). (Pubitemid 36917806)
9. Schonbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58(1), 4-43 (2001). (Pubitemid 32143961)
10. Banchereau J, Bazan F, Blanchard D et al. The CD40 antigen and its ligand. Annu. Rev. Immunol. 12, 881-922 (1994). (Pubitemid 24140434)
11. Van Kooten C, Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 67(1), 2-17 (2000). (Pubitemid 30046812)
12. Pellat-Deceunynck C, Bataille R, Robillard N et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood 84(8), 2597-2603 (1994). (Pubitemid 24317392)
13. Tai YT, Podar K, Mitsiades N et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 101(7), 2762-2769 (2003). (Pubitemid 36857641)
14. Tai YT, Podar K, Gupta D et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 99(4), 1419-1427 (2002). (Pubitemid 34547100)
15. Urashima M, Chauhan D, Hatziyanni M et al. CD40 ligand triggers interleukin-6 mediated B cell differentiation. Leuk. Res. 20(6), 507-515 (1996). (Pubitemid 26254540)
16. Law CL, Gordon KA, Collier J et al. Preclinical anti lymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 65(18), 8331-8338 (2005). (Pubitemid 41330598)
17. Tai YT, Catley LP, Mitsiades CS et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 64(8), 2846-2852 (2004). (Pubitemid 38500624)
18. Hayashi T, Treon SP, Hideshima T et al. Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br. J. Haematol. 121(4), 592-596 (2003). (Pubitemid 36645380)
19. Tai YT, Li X, Tong X et al. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 65(13), 5898-5906 (2005). (Pubitemid 40911196)
20. Horton HM, Bernett MJ, Peipp M et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116(16), 3004-3012 (2010).
21. Tai YT, Li XF, Catley L et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 65(24), 11712-11720 (2005). (Pubitemid 41821732)
22. Agura E, Niesvizky R, Matous J et al. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a Phase 1b study. Presented at: 51st American Society of Hematology (ASH) Annual Meeting. New Orleans, LA, USA, 5-8 December 2009 (Abstract 2870).
23. Ocio EM, Mateos MV, Maiso P, Pandiella A, San-Miguel JF. New drugs in multiple myeloma: mechanisms of action and Phase I/II clinical findings. Lancet Oncol. 9(12), 1157-1165 (2008).
24. Tai YT, Dillon M, Song W et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 112(4), 1329-1337 (2008).
25. Tai YT, Soydan E, Song W et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 113(18), 4309-4318 (2009).
26. Hsi ED, Steinle R, Balasa B et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin. Cancer Res. 14(9), 2775-2784 (2008).
27. Rice A, Dylan M, Van Abbema A et al. Eradication of tumors in pre-clinical models of multiple myeloma by anti-CS1 monoclonal antibody HuLuc63: mechanism of action studies. Presented at: 48th American Society of Hematology (ASH) Annual Meeting. Orlando, FL, USA, 9-11 December 2006 (Abstract 3503).
28. Bensinger W, Zonder J, Singhal S et al. Phase I trial of HuLuc63 in multiple myeloma. Presented at: 49th American Society of Hematology (ASH) Annual Meeting. Atlanta, GA, USA, 8-11 December 2007 (Abstract 1180).
29. Zonder JA, Singhal S, Bensinger W et al. Phase I study of elotuzumab (HuLuc63) in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 112(11), Abstract 2773 (2008).
30. Jakubowiak AJ, Benson DM Jr, Bensinger W et al. Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: updated results of a Phase 1 study. Blood (ASH Annual Meeting Abstracts) 116(21), Abstract 3023 (2010).
31. Lonial S, Vij R, Harousseau J-L et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma: results of a Phase 1 study. Blood (ASH Annual Meeting Abstracts) 116(21), Abstract 1936 (2010).
32. Richardson PG, Moreau P, Jakubowiak AJ et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a Phase 2 study. Blood (ASH Annual Meeting Abstracts) 116(21), Abstract 986 (2010).
33. Wijdenes J, Vooijs WC, Clement C et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br. J. Haematol. 94(2), 318-323 (1996). (Pubitemid 26247990)
34. Dhodapkar MV, Kelly T, Theus A, Athota AB, Barlogie B, Sanderson RD. Elevated levels of shed syndecan-1 correlate with tumour mass and decreased matrix metalloproteinase-9 activity in the serum of patients with multiple myeloma. Br. J. Haematol. 99(2), 368-371 (1997). (Pubitemid 27497569)
35. Bayer-Garner IB, Sanderson RD, Dhodapkar MV, Owens RB, Wilson CS. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions. Mod. Pathol. 14(10), 1052-1058 (2001). (Pubitemid 32976795)
36. Seidel C, Sundan A, Hjorth M et al. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95(2), 388-392 (2000). (Pubitemid 30041645)
37. Yang Y, Yaccoby S, Liu W et al. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood 100(2), 610-617 (2002). (Pubitemid 34761126)
38. Post J, Vooijs WC, Bast BJ, De Gast GC. Efficacy of an anti-CD138 immunotoxin and doxorubicin on drug-resistant and drug-sensitive myeloma cells. Int. J. Cancer 83(4), 571-576 (1999). (Pubitemid 29489875)
39. Ragnarsson L, Stromberg T, Wijdenes J, Totterman TH, Weigelt C. Multiple myeloma cells are killed by syndecan-1-directed superantigen-activated T cells. Cancer Immunol. Immunother. 50(7), 382-390 (2001). (Pubitemid 32835348)
40. Tassone P, Goldmacher VS, Neri P et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood 104(12), 3688-3696 (2004). (Pubitemid 39564446)
41. Dhodapkar KM, Krasovsky J, Williamson B, Dhodapkar MV. Antitumor monoclonal antibodies enhance cross-presentation of cellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J. Exp. Med. 195(1), 125-133 (2002). (Pubitemid 34074502)
42. Stein R, Mattes MJ, Cardillo TM et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res. 13(18 Pt 2), 5556s-5563s (2007). (Pubitemid 47510387)
43. Stein R, Qu Z, Cardillo TM et al. Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 104(12), 3705-3711 (2004). (Pubitemid 39564448)
44. Sapra P, Stein R, Pickett J et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin. Cancer Res. 11(14), 5257-5264 (2005). (Pubitemid 41003714)
45. Florena AM, Tripodo C, Miceli L, Ingrao S, Porcasi R, Franco V. Identification of CD162 in plasma-cell dyscrasia. Lancet Oncol. 6(8), 632 (2005). (Pubitemid 41051943)
46. Tripodo C, Florena AM, Macor P et al. P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma. Curr. Cancer Drug Targets 9(5), 617-625 (2009).
47. Ringhoffer M, Blumstein N, Neumaier B et al. 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a Phase I-II study. Br. J. Haematol. 130(4), 604-613 (2005). (Pubitemid 43899765)
48. Zhang MM, Gopal AK. Radioimmunotherapy-based conditioning regimens for stem cell transplantation. Semin. Hematol. 45(2), 118-125 (2008). (Pubitemid 351444840)
49. Lee C, Guinn BA, Brooks SE, Richardson D, Orchard K. CD66a (CEACAM1) is the only CD66 variant expressed on the surface of plasma cells in multiple myeloma: a refined target for radiotherapy trials? Br. J. Haematol. 149(5), 795-796 (2010).
50. Bjorkman PJ, Burmeister WP. Structures of two classes of MHC molecules elucidated: crucial differences and similarities. Curr. Opin Struct. Biol. 4(6), 852-856 (1994).
51. Cooper EH, Plesner T. Beta-2-microglobulin review: its relevance in clinical oncology. Med. Pediatr. Oncol. 8(4), 323-334 (1980). (Pubitemid 11138381)
52. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93(1), 55-65 (1999). (Pubitemid 29019388)
53. Yang J, Qian J, Wezeman M et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 10(4), 295-307 (2006). (Pubitemid 44512192)
54. Yang J, Zhang X, Wang J et al. Anti beta2-microglobulin monoclonal antibodies induce apoptosis in myeloma cells by recruiting MHC class I to and excluding growth and survival cytokine receptors from lipid rafts. Blood 110(8), 3028-3035 (2007). (Pubitemid 350006957)
55. Sekimoto E, Ozaki S, Ohshima T et al. A single-chain Fv diabody against human leukocyte antigen-A molecules specifically induces myeloma cell death in the bone marrow environment. Cancer Res. 67(3), 1184-1192 (2007).
56. Cao Y, Lan Y, Qian J et al. Targeting cell surface beta2-microglobulin by pentameric IgM antibodies. Br. J. Haematol. 154(1), 111-121 (2011).
57. Bergsagel PL, Smith AM, Szczepek A, Mant MJ, Belch AR, Pilarski LM. In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain. Blood 85(2), 436-447 (1995).
58. Vooijs WC, Schuurman HJ, Bast EJ, De Gast GC. Evaluation of CD38 as target for immunotherapy in multiple myeloma. Blood 85(8), 2282-2284 (1995).
59. Deaglio S, Mehta K, Malavasi F. Human CD38: a (r)evolutionary story of enzymes and receptors. Leuk. Res. 25(1), 1-12 (2001). (Pubitemid 32012975)
60. Stevenson FK, Bell AJ, Cusack R et al. Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody. Blood 77(5), 1071-1079 (1991).
61. Ellis JH, Barber KA, Tutt A et al. Engineered anti-CD38 monoclonal antibodies for immunotherapy of multiple myeloma. J. Immunol. 155(2), 925-937 (1995).
62. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am. J. Clin. Pathol. 121(4), 482-488 (2004). (Pubitemid 38392955)
63. Stevenson GT. CD38 as a therapeutic target. Mol. Med. 12(11-12), 345-346 (2006). (Pubitemid 46489831)
64. De Weers M, Tai YT, Van Der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 186(3), 1840-1848 (2011).
65. Gimsing P, Plesner T, Nahi H et al. A Phase I/II, dose-escalation study of daratumumab, a CD38 mAb in patients with multiple myeloma-preliminary safety data. Presented at: ASH Annual Meeting. San Diego, CA, USA, 10-13 December 2011 (Abstract 1873).
66. Plesner T, Lokhorst H, Gimsing P, Nahi H, Lisby S, Richardson P. Daratumumab, a CD38 mAb, for the treatment of relapsed/refractory multiple myeloma patients: preliminary efficacy data from a multicenter Phase I/II study. Presented at: ASCO Annual Meeting. Chicago, IL, USA, 1-5 June 2012 (Abstract 8019).
67. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 104(3), 607-618 (2004). (Pubitemid 38970551)
68. Van der Veer MS, de Weers M, van Kessel B et al. Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab. Haematologica 96(2), 284-290 (2011).
69. Mutis T, de Weers M, van der Veer MS et al. The potential of the human CD38-specific antibody daratumumab to improve the antimyeloma effect of novel multidrug therapies including patients refractory to lenalidomide or bortezomib. J. Clin. Oncol. 29(15 Suppl.), e18571 (2011).
70. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl Acad. Sci. USA 99(19), 12293-12297 (2002).
71. Hardy B, Kovjazin R, Raiter A, Ganor N, Novogrodsky A. A lymphocyte-activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc. Natl Acad. Sci. USA 94(11), 5756-5760 (1997). (Pubitemid 27241843)
72. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008).
73. Benson DM Jr, Bakan CE, Mishra A et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116(13), 2286-2294 (2010).
74. Trikha M, Corringham R, Klein B, Rossi JF. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res. 9(13), 4653-4665 (2003). (Pubitemid 37323267)
75. Rossi JF, Manges RF, Sutherland HJ et al. Preliminary results of CNTO 328, an anti-interleukin-6 monoclonal antibody, in combination with bortezomib in the treatment of relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 112(11), Abstract 867 (2008).
76. Orlowski RZ, Gercheva L, Williams C et al. Phase II, randomized, double blind, placebo-controlled study comparing siltuximab plus bortezomib versus bortezomib alone in pts with relapsed/refractory multiple myeloma. J. Clin. Oncol. 30(15 Suppl.), Abstract 8018 (2012).
77. Voorhees PM, Sonneveld P, Jagannath S et al. A Phase 2 multicenter study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 118(21), Abstract 3971 (2011).
78. Moreau P, Harousseau JL, Wijdenes J, Morineau N, Milpied N, Bataille R. A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma. Br. J. Haematol. 109(3), 661-664 (2000). (Pubitemid 30415199)
79. Moreau P, Hullin C, Garban F et al. Tandem autologous stem cell transplantation in high-risk de novo multiple myeloma: final results of the prospective and randomized IFM 99-04 protocol. Blood 107(1), 397-403 (2006). (Pubitemid 43053569)
80. Rossi JF, Fegueux N, Lu ZY et al. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplant. 36(9), 771-779 (2005). (Pubitemid 41613299)
81. Hunsucker SA, Magarotto V, Kuhn DJ et al. Blockade of interleukin-6 signalling with siltuximab enhances melphalan cytotoxicity in preclinical models of multiple myeloma. Br. J. Haematol. 152(5), 579-592 (2011).
82. Yoshio-Hoshino N, Adachi Y, Aoki C, Pereboev A, Curiel DT, Nishimoto N. Establishment of a new interleukin-6 (IL-6) receptor inhibitor applicable to the gene therapy for IL-6-dependent tumor. Cancer Res. 67(3), 871-875 (2007).
83. Fulciniti M, Hideshima T, Vermot-Desroches C et al. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin. Cancer Res. 15(23), 7144-7152 (2009).
84. Ishii T, Chanan-Khan A, Jafferjee J et al. A humanized anti-ganglioside GM2 antibody, BIW-8962, exhibits ADCC/CDC activity against multiple myeloma cells and potent anti-tumor activity in mouse xenograft models. Blood (ASH Annual Meeting Abstracts) 112(11), Abstract 1718 (2008).
85. Moreaux J, Hose D, Reme T et al. CD200 is a new prognostic factor in multiple myeloma. Blood 108(13), 4194-4197 (2006). (Pubitemid 44913292)
86. Campbell KS, Purdy AK. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 132(3), 315-325 (2011).
87. Benson DM Jr, Bakan CE, Zhang S et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118(24), 6387-6391 (2011).
88. Goto T, Kennel SJ, Abe M et al. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84(6), 1922-1930 (1994). (Pubitemid 24286144)
89. Ohtomo T, Sugamata Y, Ozaki Y et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 258(3), 583-591 (1999). (Pubitemid 29290312)
90. Tai YT, Horton HM, Kong SY et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood 119(9), 2074-2082 (2012).
91. Lazar GA, Dang W, Karki S et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103(11), 4005-4010 (2006).
92. Horton HM, Bernett MJ, Pong E et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 68(19), 8049-8057 (2008).
93. Lambert JM. Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin Pharmacol. 5(5), 543-549 (2005). (Pubitemid 41258574)
94. Senter PD. Potent antibody drug conjugates for cancer therapy. Curr. Opin Chem. Biol. 13(3), 235-244 (2009).
95. Chari RV. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41(1), 98-107 (2008).
96. Lutz RJ, Whiteman KR. Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs 1(6), 548-551 (2009).
97. Erickson HK, Park PU, Widdison WC et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res. 66(8), 4426-4433 (2006).
98. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J. Immunol. 130(6), 2947-2951 (1983). (Pubitemid 13107737)
99. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J. Immunol. 136(12), 4480-4486 (1986). (Pubitemid 16090665)
100. Harada H, Kawano MM, Huang N et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood 81(10), 2658-2663 (1993). (Pubitemid 23147570)
101. Tassone P, Gozzini A, Goldmacher V et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3- mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 64(13), 4629-4636 (2004). (Pubitemid 38856937)
102. Rawstron AC, Owen RG, Davies FE et al. Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage. Br. J. Haematol. 97(1), 46-55 (1997). (Pubitemid 27179563)
103. Sahara N, Takeshita A, Shigeno K et al. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma. Br. J. Haematol. 117(4), 882-885 (2002). (Pubitemid 34639251)
104. Ely SA, Knowles DM. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. Am. J. Pathol. 160(4), 1293-1299 (2002). (Pubitemid 34411633)
105. Lutz R, Ab O, Foley K et al. Efficacy of the huN901-DM1 conjugate in combination with antineoplastic agents against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts 2007, Abstract 5577 (2007).
106. Whiteman K, Ab O, Bartle L, Foley K, Goldmacher V, Lutz R. Efficacy of IMGN901 (huN901-DM1) in combination with bortezomib and lenalidomide against multiple myeloma cells in preclinical studies. AACR Meeting Abstracts 2008, Abstract 2146 (2008).
107. Ikeda H, Hideshima T, Fulciniti M et al. The monoclonal antibody nBT062 conjugated to cytotoxic maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin. Cancer Res. 15(12), 4028-4037 (2009).
108. Palumbo A, Anderson K. Multiple myeloma. N. Engl. J. Med. 364(11), 1046-1060 (2011).
109. Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol. Dis. 32(2), 290-292 (2004). (Pubitemid 38296693)
110. Sezer O. Myeloma bone disease. Hematology 10(Suppl. 1), 19-24 (2005). (Pubitemid 41825682)
111. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 7(8), 585-598 (2007). (Pubitemid 47106630)
112. Coleman RE, Major P, Lipton A et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J. Clin. Oncol. 23(22), 4925-4935 (2005). (Pubitemid 46223998)
113. Pearse RN, Sordillo EM, Yaccoby S et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl Acad. Sci. USA 98(20), 11581-11586 (2001). (Pubitemid 32928771)
114. Vanderkerken K, De Leenheer E, Shipman C et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 63(2), 287-289 (2003). (Pubitemid 36152481)
115. Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br. J. Haematol. 138(5), 563-579 (2007). (Pubitemid 47208476)
116. Filla MS, Dam P, Rapraeger AC. The cell surface proteoglycan syndecan-1 mediates fibroblast growth factor-2 binding and activity. J. Cell. Physiol. 174(3), 310-321 (1998). (Pubitemid 28068708)
117. Jakobsson L, Kreuger J, Holmborn K et al. Heparan sulfate in trans potentiates VEGFR-mediated angiogenesis. Dev. Cell 10(5), 625-634 (2006).
118. Jakob C, Wernecke T, Sterz J et al. An angiogenic risk score improves the prognostic information of the international staging system in patients with symptomatic multiple myeloma. Blood (ASH Annual Meeting Abstracts) 114(22), Abstract 2802 (2009).
119. Podar K, Tai YT, Davies FE et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood 98(2), 428-435 (2001).
120. Koldehoff M, Beelen DW, Elmaagacli AH. Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma. J. Leukoc. Biol. 84(2), 561-576 (2008).
121. Ria R, Vacca A, Russo F et al. A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. Thromb. Haemost. 92(6), 1438-1445 (2004). (Pubitemid 39642557)
122. Raschko M, Markovina S, Miyamoto S et al. Phase II trial of bevacizumab combined with low dose dexamethasone and lenalidomide (BEV/REV/DEX) for relapsed or refractory myeloma (MM). Blood (ASH Annual Meeting Abstracts) 110(11), Abstract 1173 (2007).
123. Callander NS, Markovina S, Juckett MB et al. The addition of bevacizumab (B) to lenalidomide and low dose dexamethasone does not significantly increase response in relapsed or refractory multiple myeloma (NCI#7317). Blood (ASH Annual Meeting Abstracts) 114(22), Abstract 3885 (2009).
124. Weber DM, Chen C, Niesvizky R et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N. Engl. J. Med. 357(21), 2133-2142 (2007). (Pubitemid 350146108)
125. Beenken A, Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 8(3), 235-253 (2009).
126. Chang H, Stewart AK, Qi XY, Li ZH, Yi QL, Trudel S. Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood 106(1), 353-355 (2005). (Pubitemid 40967212)
127. Hadari Y, Schlessinger J. FGFR3-targeted mAb therapy for bladder cancer and multiple myeloma. J. Clin. Invest. 119(5), 1077-1079 (2009).
128. Lamorte S, Ferrero S, Aschero S et al. Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells. Leukemia 26(5), 1081-1090 (2012).
129. Sanderson RD, Yang Y, Kelly T, Macleod V, Dai Y, Theus A. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell. Biochem. 96(5), 897-905 (2005). (Pubitemid 41688716)
130. Ostrovsky O, Korostishevsky M, Levite I et al. Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 21(11), 2296-2303 (2007). (Pubitemid 350011702)
131. Dai Y, Yang Y, Macleod V et al. HSulf-1 and HSulf-2 are potent inhibitors of myeloma tumor growth in vivo. J. Biol. Chem. 280(48), 40066-40073 (2005). (Pubitemid 41779141)
132. Huang HB, Zhan R. Effect of VEGF antisense RNA on inducing apoptosis of myeloma cells and inhibition of angiogenesis in endothelial cells in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(2), 312-316 (2008).
133. Podar K, Zimmerhackl A, Fulciniti M et al. The selective adhesion molecule inhibitor natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br. J. Haematol. 155(4), 438-448 (2011).
134. Tassone P, Neri P, Carrasco DR et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106(2), 713-716 (2005). (Pubitemid 40981270)
135. Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: a review. Crit. Rev. Oncol. Hematol. 56(3), 365-378 (2005). (Pubitemid 41677618)
136. Vij R, Horvath N, Spencer A et al. An open-label, Phase II trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am. J. Hematol. 84(10), 650-656 (2009).
137. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29(9), 1125-1132 (2011).
138. Tian E, Zhan F, Walker R et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med. 349(26), 2483-2494 (2003). (Pubitemid 38010074)
139. Giuliani N, Morandi F, Tagliaferri S et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 67(16), 7665-7674 (2007). (Pubitemid 47281359)
140. Qiang YW, Barlogie B, Rudikoff S, Shaughnessy JD Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone 42(4), 669-680 (2008).
141. Qian J, Xie J, Hong S et al. Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma. Blood 110(5), 1587-1594 (2007). (Pubitemid 47443975)
142. Fulciniti M, Tassone P, Hideshima T et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114(2), 371-379 (2009).
143. Heath DJ, Chantry AD, Buckle CH et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res. 24(3), 425-436 (2009).
144. Gahrton G, Tura S, Ljungman P et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N. Engl. J. Med. 325(18), 1267-1273 (1991).
145. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 109(8), 3588-3594 (2007). (Pubitemid 46572554)
146. Corradini P, Voena C, Tarella C et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J. Clin. Oncol. 17(1), 208-215 (1999). (Pubitemid 29022395)
147. Martinelli G, Terragna C, Zamagni E et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J. Clin. Oncol. 18(11), 2273-2281 (2000). (Pubitemid 30350220)
148. Harrison SJ, Cook G. Immunotherapy in multiple myeloma-possibility or probability? Br. J. Haematol. 130(3), 344-362 (2005).
149. Shimoni A, Hardan I, Ayuk F et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer 116(15), 3621-3630 (2010).
150. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br. J. Haematol. 113(1), 209-216 (2001). (Pubitemid 32423325)
151. Garban F, Attal M, Michallet M et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 107(9), 3474-3480 (2006).
152. Kroger N, Einsele H, Wolff D et al. Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A Phase I/II study of the German Study-group Multiple Myeloma (DSMM). Bone Marrow Transplant. 31(11), 973-979 (2003). (Pubitemid 36722408)
153. Kroger N, Schwerdtfeger R, Kiehl M et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 100(3), 755-760 (2002). (Pubitemid 34832597)
154. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: proof of principle. Blood 87(3), 1196-1198 (1996). (Pubitemid 26043549)
155. Corradini P, Cavo M, Lokhorst H et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 102(5), 1927-1929 (2003). (Pubitemid 37022595)
156. Lokhorst HM, Wu K, Verdonck LF et al. The occurrence of graft-versus-host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood 103(11), 4362-4364 (2004). (Pubitemid 38685385)
157. Salama M, Nevill T, Marcellus D et al. Donor leukocyte infusions for multiple myeloma. Bone Marrow Transplant. 26(11), 1179-1184 (2000).
158. Ayuk F, Shimoni A, Nagler A et al. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma. Leukemia 18(3), 659-662 (2004). (Pubitemid 38425889)
159. Peggs KS, Mackinnon S, Williams CD et al. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity. Biol. Blood Marrow Transplant. 9(4), 257-265 (2003). (Pubitemid 40045612)
160. Kroger N, Kruger W, Renges H et al. Donor lymphocyte infusion enhances remission status in patients with persistent disease after allografting for multiple myeloma. Br. J. Haematol. 112(2), 421-423 (2001). (Pubitemid 32184333)
161. Kroger N, Badbaran A, Lioznov M et al. Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma. Exp. Hematol. 37(7), 791-798 (2009).
162. Gozzetti A, Fabbri A, Lazzi S, Bocchia M, Lauria F. Reply to 'Rituximab activity in CD20-positive multiple myeloma'. Leukemia 22(5), 1083; author reply 1083-1084 (2008). (Pubitemid 351689900)
163. Huff CA, Matsui W. Multiple myeloma cancer stem cells. J. Clin. Oncol. 26(17), 2895-2900 (2008).
164. Johansson SE, Hejdeman B, Hinkula J et al. NK cell activation by KIR-binding antibody 1-7F9 and response to HIV-infected autologous cells in viremic and controller HIV-infected patients. Clin. Immunol. 134(2), 158-168 (2010).
165. Romagne F, Andre P, Spee P et al. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells. Blood 114(13), 2667-2677 (2009).
166. Van Rhee F, Szmania SM, Dillon M et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol. Cancer Ther. 8(9), 2616-2624 (2009).